Content about Actinic keratosis

December 12, 2012
Galderma Pharma to acquire Spirig Pharma

Swiss skin drug maker Galderma Pharma will acquire another Swiss drug maker also focused on treatments for skin conditions, Galderma said.

LAUSANNE, Switzerland — Swiss skin drug maker Galderma Pharma will acquire another Swiss drug maker also focused on treatments for skin conditions, Galderma said.

Based in Egerkingen, Switzerland, Spirig makes treatments for such conditions as solar damage and skin barrier function impairment, as well as treatments for such precancerous conditions as actinic keratosis. Financial terms of the deal were not disclosed, though it was noted that Spirig had sales of about $106 million in 2011. The global corporate headquarters of Galderma will remain in Lausanne, Switzerland.

September 4, 2012
Valeant buys Medicis for $2.6 billion

Canadian drug maker Valeant Pharmaceuticals International is buying Medicis Pharmaceutical for $2.6 billion, Valeant said Monday.

MONTREAL — Canadian drug maker Valeant Pharmaceuticals International is buying Medicis Pharmaceutical for $2.6 billion, Valeant said Monday.

The $44-per-share deal, which the companies said represents a 39% premium over the closing price of Medicis' shares on Friday, is expected to close in the first half of 2013.

February 6, 2012
Mylan acquires rights to two Valeant drugs

Mylan has completed its acquisition of two skin drugs from Valeant Pharmaceuticals, the generic drug maker said Monday.

PITTSBURGH — Mylan has completed its acquisition of two skin drugs from Valeant Pharmaceuticals, the generic drug maker said Monday.

Mylan announced that it had acquired the regulatory approval applications for generic clindamycin phosphate and benzoyl peroxide gel, a generic version of Valeant's BenzaClin, and a license to manufacture and market fluorouracil cream in the 5% strength, a version of Valeant's Efudex.

January 25, 2012
FDA approves actinic keratosis treatment

The Food and Drug Administration has approved a topical treatment made by Leo Pharma for a skin condition that can lead to cancer, the drug maker said Wednesday.

PARSIPPANY, N.J. — The Food and Drug Administration has approved a topical treatment made by Leo Pharma for a skin condition that can lead to cancer, the drug maker said Wednesday.

Leo announced the FDA approval of Picato (ingenol mebutate) gel in the 0.015%/0.05% strength for actinic keratosis, also known as AK, which is a precancerous condition resulting from cumulative sun exposure that has the potential to lead to squamous cell carcinoma.

December 13, 2011
FTC approves Valeant's acquisitions of Dermik, Ortho Dermatologics

The Federal Trade Commission has voted to approve Valeant's acquisitions of Dermik, a unit of French drug maker Sanofi that makes drugs for skin conditions, and Ortho Dermatologics, a division of Johnson & Johnson that also makes skin drugs.

MISSISSAUGA, Ontario — The Federal Trade Commission has voted to approve Valeant's acquisitions of Dermik, a unit of French drug maker Sanofi that makes drugs for skin conditions, and Ortho Dermatologics, a division of Johnson & Johnson that also makes skin drugs.

July 19, 2011
Graceway receives regulatory approval for Zyclara

The Food and Drug Administration has approved a drug made by Graceway Pharmaceuticals for actinic keratoses, Graceway said.

BRISTOL, Tenn. — The Food and Drug Administration has approved a drug made by Graceway Pharmaceuticals for actinic keratoses, Graceway said.

The agency approved Zyclara (imiquimod) cream in the 2.5% strength for AK, a precancerous lesion that affects about 10 million Americans and can develop into skin cancer later on.

April 18, 2011
Taro receives FDA approval for generic Aldara

The Food and Drug Administration has approved a topical treatment for skin conditions made by Israeli generic drug maker Taro Pharmaceutical Industries.

HAWTHORNE, N.Y. — The Food and Drug Administration has approved a topical treatment for skin conditions made by Israeli generic drug maker Taro Pharmaceutical Industries.

Taro announced Monday the approval of imiquimod cream in the 5% strength. The drug is used to treat actinic keratosis and external genital warts, and is a generic version of Graceway Pharmaceuticals’ Aldara.

Imiquimod cream has annual sales of around $340 million in the United States, according to Taro.

September 8, 2010
Perrigo gets approval for generic Aldara

The Food and Drug Administration has approved a generic drug for treating skin diseases made...

ALLEGAN, Mich. The Food and Drug Administration has approved Perrigo's generic drug for treating skin diseases, the drug maker said Wednesday.

 

The FDA approved Perrigo’s imiquimod cream in the 5% strength. The drug is a generic version of Graceway Pharmaceuticals’ Aldara.

 

 

The drug is used to treat actinic keratoses on the face and scalp, superficial basal cell carcinoma and external genital and perianal warts in patients ages 12 years and older.

 

March 28, 2010
FDA approves Zyclara

The Food and Drug Administration has approved a new drug made by Graceway Pharmaceuticals for...

March 7, 2010
Taro receives FDA approval for skin cancer generic

The Food and Drug Administration has approved Taro Pharmaceutical Industries’ generic version of a drug...

February 25, 2010
Fougera receives FDA approval for generic Aldara

The Food and Drug Administration has given E. Fougera & Co. approval for the first...